@FierceMedDev: Editor's Corner: Germany's Epigenomics is betting its future on an early-detection colon cancer Dx. Feature | Follow @FierceMedDev
@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. Yesterday's story | Follow @DamianFierce
> Cook Medical is launching its Hercules esophageal balloon to treat patients with gastrointestinal strictures. News
> Germany's MagForce has appointed former Fresenius CEO Ben Lipps to be the company's next chief executive. Story
> Life Technologies ($LIFE) has licensed out its Invivofectamine technology to a Chinese drugmaker to develop siRNA treatments. More
> Castle Biosciences has launched DecisionDx-EC, a diagnostic designed to determine whether esophageal cancer patients will respond to chemoradiation therapy. Release
> Beckman Coulter won FDA clearance for a new myocardial infarction diagnostic test. More
> ArtVentive Medical won a CE mark for its self-expanding catheter. Article
> Becton Dickinson's ($BDX) growing bioscience unit launched a new cell analyzer, marketing the BD LSRFortessa X-20 as more compact than its competitors. Item
Biotech News
@FierceBiotech: Join what is probably one of the fastest-growing LinkedIn groups in biotech, & learn the meaning of life... sciences. Join now | Follow @FierceBiotech
@JohnCFierce: Man, oh man. Bluebird IPO busts out, raises $101M as biotech offerings turn red hot - $BLUE up 50%. News | Follow @JohnCFierce
@RyanMFierce: W/ $BLUE out, DMD drug developer Prosensa moves up in the biotech IPO queue, sets terms for $60M deal: More | Follow @RyanMFierce
@EmilyMFierce: This week's issue of FierceBiotechResearch is out: Alzheimer's drug restores links in brain and more: This week's news | Follow @EmilyMFierce
> Sarepta shares spike on upbeat results from DMD extension study. News
> NIH backs pharma giants and academics' projects to revive R&D castoffs. Article
> Analysis: AMA decision on obesity will boost drug R&D in a troubled field. Editor's corner
> Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround. Story
Pharma News
@FiercePharma: More Novo Nordisk bad news: Loses Prandin patent fight in U.S. Circuit court, $200m sales at risk. Report | Follow @FiercePharma
@EricPFierce: U.K. gets nervous on looming deadline for API certifications, outlines contingency plan. Yesterday's report | Follow @EricPFierce
> Biogen's impressive Tecfidera launch hits reimbursement, supply snags. Article
> Onglyza fails outcomes trial in a $1B hit for Bristol-Myers, AstraZeneca. Story
> Use prescription meds properly, save $200 billion a year. Report
Drug Delivery News
@MichaelGFierce: Self-propelled, spinning 'nano-necklaces' could pinpoint drug delivery. More | Follow @MichaelGFierce
> BD, JDRF partner to join artificial pancreas race. More
> Capsugel launches Lipidex platform for greater oral stability, potency. Item
> Teva grabs MicroDose respiratory biz with inhaled delivery platform. Article
> Drug-carrying 'nanovolcanoes' make precise delivery structures. Story